Fig. 4From: Cancer cell-specific and pro-apoptotic SMAC peptide-doxorubicin conjugated prodrug encapsulated aposomes for synergistic cancer immunotherapyTumor targeting of Aposomes in colon tumor models. a NIRF images of CT26 colon tumor-bearing mice after treatment with saline or an equivalent DOX dose (3 mg/kg) of free DOX, DOXIL or Aposomes. b Quantitative analyses for DOX fluorescence signals within the tumor regions of CT26 colon tumor-bearing mice after treatment with saline or an equivalent DOX dose (3 mg/kg) of free DOX, DOXIL or Aposomes. c Fluorescence images and quantitative analyses of exercised tumor tisseus from CT26 colon tumor-bearing mice after treatment with saline or an equivalent DOX dose (3 mg/kg) of free DOX, DOXIL or Aposomes for 24 h. d Histological analyses of tumor tissues from CT26 colon tumor-bearing mice after treatment with saline or an equivalent DOX dose (3 mg/kg) of free DOX, DOXIL or Aposomes for 24 h. e, f Ex vivo fluorescence images of CT26 colon tumor-bearing mice after treatment with saline or an equivalent DOX dose (3 mg/kg) of free DOX, DOXIL or Aposomes. Significance was determined by Tukey − Kramer post-hoc testBack to article page